Pulmonary Medicine

Below are current clinical trials.

Filter this list of studies by location, status and more.

1. Impulse Oscillometry in Idiopathic Subglottic StenosisCap

   Rochester, Minn.

   The purpose of this study is to describe impulse oscillometry (IOS) in patients with symptomatic idiopathic subglottic stenosis (iSGS). The study will also compare IOS findings in patients with iSGS with IOS findings in patients with small airways obstruction and in healthy controls.

    

2. A Study of Beta-Blockers for the Prevention of Acute Worsening of Chronic Obstructive Pulmonary Disease

   Rochester, Minn.

   The purpose of this study is to assess the effect of metoprolol for patients who have moderate to severe COPD, measuring the time to first acute exacerbation (episode of worsening), the rates and severity of exacerbations, any cardiovascular events, all-causes of death, lung function, difficulty breathing, quality of life and any metoprolol-related side effects.

3. A One-Time DNA Study for Vasculitis

   Rochester, Minn.

   The purpose of this study is to identify genes that increase the risk of developing vasculitis, a group of severe diseases that feature inflammation of blood vessels. Results of these studies will provide vasculitis researchers with insight into the causes of these diseases and generate new ideas for diagnostic tests and therapies, and will be of great interest to the larger communities of researchers investigating vasculitis and other autoimmune, inflammatory, and vascular diseases.

4. Trametinib, Combination Chemotherapy, and Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery

   Rochester, Minn.

   This phase I trial studies the side effects and the best dose of trametinib when given together with combination chemotherapy and radiation therapy in treating patients with stage III non-small cell lung cancer that cannot be removed by surgery. Trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x-rays to kill tumor cells. Giving trametinib, combination chemotherapy, and radiation therapy may be a better treatment for non-small cell lung cancer.

5. Influence of Immunosuppresion on Lung Iron Content in Pneumonia

   Scottsdale/Phoenix, Ariz.

   The purpose of the study is to see whether lung concentrations of iron and a protein that binds iron are influenced by the presence of pneumonia. Increased amounts of iron in the lungs may promote the growth or microorganisms and may influence the severity of lung injury caused by an infection. We are comparing the amount of iron that accumulates in the lungs in response to pneumonia in different types of patients.

6. Decision Aid for Shared Decision Making in Acute Respiratory Failure

   Rochester, Minn.

   The purpose of this study is to develop, in close collaboration with stakeholders, an evidence-based decision aid for patients with acute respiratory failure.  To evaluate the impact of the decision aid on patient-important outcomes. We will conduct a prospective trial assessing the impact of the decision aid (vs. usual specialist care) on patient knowledge, patient involvement in decision-making, decision quality, treatment choice, and patient outcomes.

7. Patient Centered Outcomes for Life Support RETROSPECTIVE

   Rochester, Minn.

   The purpose of this study is to identify and prioritize outcomes and burdens of treatment that are important to patients and families when making decisions to start versus withhold or continue versus withdraw life support in the intensive care unit.

    

    

8. Sleep-Related Determinants of Stroke

   Scottsdale/Phoenix, Ariz.

   Stroke is the second leading cause of death worldwide. Traditional stroke risk factors explain about half of the risk for stroke. The remaining half may be partially explained by sleep duration and disturbances, which are prospectively related to incident stroke across multiple populations. Although these relationships have been identified, at present, essentially nothing is known regarding the modifiable, sleep-inhibiting behaviors that determine sleep duration and disruption; these are probable targets of stroke prevention. The study proposed here is intended to fill this void by determining the relation between sleep-inhibiting behaviors, self-reported sleep duration and disruption, and stroke amongst acute stroke inpatients.

9. Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON)

   Scottsdale/Phoenix, Ariz., Jacksonville, Fla., Rochester, Minn.

   This is a randomized, open-label, multi-center, global, Phase III study to determine the efficacy and safety of durvalumab + tremelimumab combination therapy + Standard of care (SoC) chemotherapy or durvalumab monotherapy + SoC chemotherapy versus SoC chemotherapy alone as first line treatment in patients with metastatic non small-cell lung cancer (NSCLC) with tumors that lack activating epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) fusions.

10. A Study to Develop a Decision Aid for Patients Having Lung Screening

    Rochester, Minn.

    The purpose of this study is to collect data and then design a decision aid for patients who are having a lung screening.